drugset / Trial / NCT04496167

Safety and Efficacy of EN3835 in Participants With Frozen Shoulder

NCT04496167

Phase 2 Completed 198 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of EN3835 for the treatment of adhesive capsulitis of the shoulder (frozen shoulder).

Timeline

Start
2020-07-29
Primary completion
2022-04-14
Completion
2022-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 1.74 mg

Indications